Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
RESEARCH TOOLSreports
Holding APLS?
Track your performance easily
APLS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$24.34 - $73.80
Previous Close$33.21
Volume3.73M
Average Volume (3M)3.41M
Market Cap
$4.12B
Enterprise Value$4.20B
Total Cash (Recent Filing)$396.90M
Total Debt (Recent Filing)$470.45M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Mar 04, 2025EPS Estimate
-$0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.04
Shares Outstanding124,393,017
10 Day Avg. Volume2,884,547
30 Day Avg. Volume3,412,704
Standard Deviation0.22
R-Squared0.05
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)17.39
Price to Sales (P/S)5.76
Price to Cash Flow (P/CF)30.20
P/FCF Ratio30.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.87
Enterprise Value/Gross Profit12.41
Enterprise Value/Ebitda-19.94
Forecast
1Y Price Target
$46.27Price Target Upside39.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
Apellis Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageSyfovre's prescribing label offers both monthly and every other month dosing, providing a competitive advantage over its main competitor Izervay, which currently only has monthly dosing.
Growth PotentialManagement is optimistic about the outlook for Syfovre, with significant opportunities for growth anticipated in the geographic atrophy market.
Market RecognitionDistinctive product label advantages for Syfovre can now be emphasized by Apellis to physicians, enhancing its competitive position and driving greater market recognition.
Bears Say
Market PerformanceThe GA market is smaller than consensus estimates, with the majority of sales growth coming from Izervay rather than Syfovre.
Sales And RevenueFlat to modest sales growth and future average selling price erosion for Syfovre are not bullish for the market in its second year.
Stock PerformanceThe disappointing 3Q results led to a significant reduction in the price target for Apellis Pharmaceuticals' stock.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
APLS FAQ
What was Apellis Pharmaceuticals Inc’s price range in the past 12 months?
Apellis Pharmaceuticals Inc lowest stock price was $24.34 and its highest was $73.80 in the past 12 months.
What is Apellis Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Apellis Pharmaceuticals Inc’s upcoming earnings report date?
Apellis Pharmaceuticals Inc’s upcoming earnings report date is Mar 04, 2025 which is in 73 days.
How were Apellis Pharmaceuticals Inc’s earnings last quarter?
Apellis Pharmaceuticals Inc released its earnings results on Nov 05, 2024. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.295 by -$0.165.
Is Apellis Pharmaceuticals Inc overvalued?
According to Wall Street analysts Apellis Pharmaceuticals Inc’s price is currently Undervalued.
Does Apellis Pharmaceuticals Inc pay dividends?
Apellis Pharmaceuticals Inc does not currently pay dividends.
What is Apellis Pharmaceuticals Inc’s EPS estimate?
Apellis Pharmaceuticals Inc’s EPS estimate is -$0.37.
How many shares outstanding does Apellis Pharmaceuticals Inc have?
Apellis Pharmaceuticals Inc has 124,393,020 shares outstanding.
What happened to Apellis Pharmaceuticals Inc’s price movement after its last earnings report?
Apellis Pharmaceuticals Inc reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.295. Following the earnings report the stock price went down -1.681%.
Which hedge fund is a major shareholder of Apellis Pharmaceuticals Inc?
Among the largest hedge funds holding Apellis Pharmaceuticals Inc’s share is Woodline Partners LP. It holds Apellis Pharmaceuticals Inc’s shares valued at 5M.
---
Apellis Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$46.27 (39.33% Upside)
$46.27 (39.33% Upside)
Blogger Sentiment
Bullish
APLS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 7.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $171.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.57%
12-Months-Change
Fundamentals
Return on Equity
-106.56%
Trailing 12-Months
Asset Growth
10.22%
Trailing 12-Months
Company Description
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
---
APLS Company Deck
---
APLS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong demand growth for SYFOVRE and promising Phase III results for Empaveli, indicating potential for significant market impact. However, these positives were offset by revenue decline for SYFOVRE due to gross to net adjustments, slowed market growth, and challenges in Europe. Overall, the company remains optimistic about long-term prospects and profitability but faces immediate hurdles.Read More>---
APLS Stock 12 Month Forecast
Average Price Target
$46.27
▲(39.33% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Crispr Therapeutics AG
―
Intellia Therapeutics
―
Best Analysts Covering APLS
1 Year
1 Year Success Rate
16/29 ratings generated profit
1 Year Average Return
+10.42%
assigned a buy rating 2 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 55.17% of your transactions generating a profit, with an average return of +10.42% per trade.
---